NASDAQ:JUNO - Juno Therapeutics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$86.96
+0.30 (1.20%)
Get New Juno Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for JUNO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for JUNO

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Juno Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $86.96.

This chart shows the closing price for JUNO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Juno Therapeutics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/24/2018Standpoint ResearchReiterated RatingBuy ➝ HoldLow
1/24/2018BarclaysDowngradeOverweight ➝ Equal Weight$55.00 ➝ $87.00Low
1/23/2018SVB LeerinkDowngradeOutperform ➝ Market Perform$56.00 ➝ $87.00Low
1/23/2018Raymond JamesDowngradeOutperform ➝ HoldLow
1/22/2018SunTrust BanksReiterated RatingBuy ➝ HoldLow
1/22/2018Needham & Company LLCDowngradeBuy ➝ HoldLow
1/22/2018GuggenheimDowngradeBuy ➝ NeutralLow
1/17/2018Raymond JamesReiterated RatingOutperform ➝ BuyHigh
1/17/2018CitigroupDowngradeBuy ➝ NeutralHigh
1/17/2018WedbushDowngradeOutperform ➝ NeutralHigh
1/17/2018Wells Fargo & CompanyReiterated RatingMarket Perform$54.00 ➝ $63.00High
1/11/2018Raymond JamesReiterated RatingBuyMedium
1/11/2018JPMorgan Chase & Co.Reiterated RatingHoldHigh
1/5/2018Needham & Company LLCInitiated CoverageBuy ➝ Buy$65.00Medium
12/13/2017Maxim GroupSet Price TargetBuy$56.00High
12/12/2017Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformHigh
12/11/2017Raymond JamesReiterated RatingBuyHigh
11/3/2017Raymond JamesBoost Price TargetOutperform$45.00 ➝ $61.00N/A
11/3/2017CowenReiterated RatingBuyN/A
11/2/2017Maxim GroupReiterated RatingBuy$56.00N/A
11/2/2017SVB LeerinkReiterated RatingOutperform ➝ In-Line$34.00 ➝ $56.00N/A
11/2/2017WedbushReiterated RatingOutperform$42.00 ➝ $64.00N/A
11/2/2017SunTrust BanksUpgradeHold ➝ BuyN/A
10/31/2017CitigroupReiterated RatingBuy$59.00N/A
10/27/2017CowenReiterated RatingBuy$49.00N/A
10/9/2017Maxim GroupReiterated RatingBuy ➝ Buy$34.00 ➝ $56.00N/A
10/6/2017The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$44.00N/A
10/6/2017Morgan StanleyReiterated RatingEqual Weight$27.00 ➝ $43.00N/A
9/6/2017BarclaysInitiated CoverageOverweight$55.00Medium
9/5/2017Wells Fargo & CompanyReiterated RatingOutperform ➝ Outperform$35.00 ➝ $54.00Low
8/31/2017Standpoint ResearchReiterated RatingBuy ➝ ReduceMedium
8/29/2017Raymond JamesUpgradeMarket Perform ➝ Outperform$45.00High
8/29/2017WedbushUpgradeNeutral ➝ Outperform$42.00 ➝ $42.00High
8/28/2017BTIG ResearchUpgradeSell ➝ NeutralHigh
8/7/2017Morgan StanleyBoost Price TargetEqual ➝ Equal Weight$26.00 ➝ $27.00Low
6/20/2017SVB LeerinkReiterated RatingOutperform$34.00Low
6/12/2017SVB LeerinkReiterated RatingOutperformLow
6/8/2017BTIG ResearchDowngradeNeutral ➝ Sell$22.60 ➝ $23.73Low
6/6/2017WedbushReiterated RatingNeutral$24.00Medium
6/6/2017BTIG ResearchDowngradeNeutral ➝ Sell$12.00 ➝ $23.00Medium
5/18/2017FBR & Co.Reiterated RatingHoldMedium
5/15/2017WedbushReiterated RatingNeutral$24.00N/A
5/8/2017Morgan StanleyLower Price TargetEqual Weight$27.00 ➝ $26.00High
5/5/2017WedbushReiterated RatingNeutral$24.00High
5/5/2017FBR & Co.Lower Price TargetMkt Perform ➝ Mkt Perform$30.00 ➝ $29.00High
4/4/2017CitigroupLower Price TargetBuy$34.00 ➝ $30.00Low
3/30/2017CowenReiterated RatingBuy$41.00 ➝ $36.00Low
3/3/2017JPMorgan Chase & Co.Reiterated RatingNeutral$34.00 ➝ $31.00N/A
3/3/2017WedbushReiterated RatingNeutral$24.00N/A
3/2/2017FBR & Co.Set Price TargetHold$30.00N/A
3/2/2017Maxim GroupSet Price TargetBuy$34.00N/A
2/22/2017Wells Fargo & CompanyInitiated CoverageOutperform ➝ OutperformN/A
2/1/2017WedbushInitiated CoverageNeutral$24.00N/A
1/11/2017JPMorgan Chase & Co.Reiterated RatingHoldN/A
12/6/2016FBR & Co.Set Price TargetHold$30.00N/A
12/6/2016Raymond JamesReiterated RatingOutperform ➝ Market PerformN/A
12/5/2016CowenReiterated RatingBuy$51.00N/A
12/5/2016Maxim GroupSet Price TargetBuy$34.00N/A
12/1/2016JPMorgan Chase & Co.Reiterated RatingHold$34.00N/A
11/28/2016SVB LeerinkReiterated RatingOutperform$45.00 ➝ $34.00N/A
11/25/2016SunTrust BanksDowngradeBuy ➝ Hold$48.00 ➝ $25.00N/A
11/24/2016JPMorgan Chase & Co.Set Price TargetHold$39.00 ➝ $34.00N/A
11/23/2016BTIG ResearchReiterated RatingNeutralN/A
11/23/2016Maxim GroupLower Price TargetBuy$50.00 ➝ $34.00N/A
11/23/2016FBR & Co.DowngradeOutperform ➝ Market Perform$30.00N/A
11/3/2016BTIG ResearchUpgradeSell ➝ NeutralN/A
(Data available from 10/23/2016 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/26/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/25/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/25/2021
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/24/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/23/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/23/2021

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Juno Therapeutics logo
Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity.
Read More

Today's Range

Now: $86.96
Low: $86.96
High: $86.96

50 Day Range

MA: $86.96
Low: $86.96
High: $86.96

52 Week Range

Now: $86.96
Low: $19.62
High: $87.01

Volume

2 shs

Average Volume

5,484,542 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Juno Therapeutics?

The following equities research analysts have issued stock ratings on Juno Therapeutics in the last twelve months:
View the latest analyst ratings for JUNO.

What is the current price target for Juno Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Juno Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Juno Therapeutics in the next year.
View the latest price targets for JUNO.

What is the current consensus analyst rating for Juno Therapeutics?

Juno Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for JUNO.

How do I contact Juno Therapeutics' investor relations team?

Juno Therapeutics' physical mailing address is 400 Dexter Ave N Ste 1200, SEATTLE, WA 98109-4703, United States. The biopharmaceutical company's listed phone number is +1-206-5821600. The official website for Juno Therapeutics is www.junotherapeutics.com.